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Abstract
Transforming growth factor-b1 (TGF-b1) is an important anti-inflammatory cytokine that modulates and resolves
inflammatory responses. Recent studies have demonstrated that inflammation enhances neoplastic risk and potentiates
tumor progression. In the evolution of cancer, pro-inflammatory cytokines such as IL-1b must overcome the anti-
inflammatory effects of TGF-b to boost pro-inflammatory responses in epithelial cells. Here we show that IL-1b or
Lipopolysaccharide (LPS) suppresses TGF-b-induced anti-inflammatory signaling in a NF-kB-independent manner. TRAF6, a
key molecule in IL-1b signaling, mediates this suppressive effect through interaction with the type III TGF-b receptor (TbRIII),
which is TGF-b-dependent and requires type I TGF-b receptor (TbRI) kinase activity. TbRI phosphorylates TbRIII at residue
S829, which promotes the TRAF6/TbRIII interaction and consequent sequestration of TbRIII from the TbRII/TbRI complex.
Our data indicate that IL-1b enhances the pro-inflammatory response by suppressing TGF-bsignaling through TRAF6-
mediated sequestration of TbRIII, which may be an important contributor to the early stages of tumor progression.
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Introduction
Transforming growth factor-(TGF-b) is an important cytokine
that plays fundamental roles in regulating cell proliferation,
apoptosis, differentiation, and migration [1]. In the canonical
signaling pathway, the TGF-b ligand directly binds to TbRII or
TbRIII which, in turn, phosphorylates and activates TbRI. The
activated TbRI recruits and phosphorylates Smad2 and Smad3
(R-Smads). These R-Smads form a complex with Smad4 which
translocates into the nucleus to regulate TGF-b target genes [2].
TbRIII was originally described as an accessory receptor because
it has no known enzymatic activity in its cytoplasmic domain and
seemed to enhance TGF-b signaling by simply presenting TGF-b
ligands to TbRII [3]. However, growing evidence indicates that
TbRIII has a more complex role in the regulation of TGF-b
signaling especially in cancer [4,5].
Aberrant TGF-b signaling, often caused by functional loss of
key signaling components, is found in a broad range of cancers.
Perturbation of TGF-b signaling, which most commonly results in
a loss of its growth inhibitory function, provides a favorable
condition for early-stage tumors to progress into malignant cancer.
Therefore, it is important to identify the regulatory mechanisms of
TGF-b signaling in the early stages of cancer development.
Persistent inflammation is closely linked to cancer progression
through its stimulation of cell proliferation, survival, invasion, and
metastasis [6,7]. In normal tissue, inflammation induced by pro-
inflammatory cytokines (e.g. IL-1b and TNF-a) is tightly regulated
by anti-inflammatory cytokines (e.g. IL-10, IL-13, and TGF-b),
which resolve the inflammatory response [8]. Therefore, it is
essential to understand the mechanisms by which these two classes
of cytokines function in a coordinate manner to maintain cellular
homeostasis.
Pro-inflammatory mediators such as IL-1b and LPS activate
NF-kB and p38/JNK pathways through the TRAF6/TAK1 axis.
It is well established that IL-1b and TGF-b have antagonistically
regulating mechanism towards one another. For example, TGF-b
inhibits IL-1b signaling by disrupting the Pellino1/IRAK1
complex by Smad6 [9], whereas TGF-b may block TNF-a
signaling through the interruption of TRAF2/TAB2 and TAB3
association by Smad7 [10]. Conversely, pro-inflammatory cyto-
kines are theorized to attenuate anti-inflammatory signals in order
to enhance inflammatory responses. Indeed, it has been suggested
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mediated Smad2/3 phosphorylation and Smad3/4-DNA binding
[11]. Also, IL-1b has been shown to inhibit Smad3-mediated
TGF-b target gene activation through its downstream effecter
TAK1 [12]. NF-kB/RelA-mediated Smad7 induction has also
been suggested as a possible means by which cells suppress TGF-
b/Smad signaling [13]. Nonetheless, the underlying mechanism
by which IL-1b attenuates anti-proliferative or apoptotic TGF-
bsignaling is not fully understood.
In this study, we demonstrate that IL-1bor LPS is able to
suppress TGF-b/Smad signaling through regulation of the TGF-b
receptor complex. We show that TRAF6 binds to TbRIII in a
TbRI kinase-dependent manner, and thereby suppresses TGF-b-
Smad2/3 signaling.
Results and Discussion
IL-1b and LPS suppress TGF-b1-Smad2/3 pathways
through TRAF6
In order to examine whether pro-inflammatory effectors (IL-
1b or LPS) are able to suppress Smad2/3-mediated TGF-b1
signaling, we treated various cells with TGF-b1 in the presence
or absence of IL-1b or LPS. Co-treatment of cells with TGF-b1
and IL-1b resulted in decreased phospho-Smad2/3 in HEK293
(Figure 1A) as well as in other cell lines such as HaCaT, 67NR,
and FaO cells (Figure S1A, S1F, and S2A). We first examined
whether TAK1, a key enzyme in pro-inflammatory signaling, is
involved in IL-1b/LPS-mediated suppression of TGF-b signaling
by using mutant TAK1 (K63W) which blocks IL-1b-mediated
NF-kB activation (Figure S1B). TAK1 (K63W) failed to abrogate
the IL-1b effect on TGF-b1/Smad signaling in SBE-luciferase
reporter gene assay (SBE-Luc) containing promoter with Smad-
binding sequences(Figure 1B). It has been reported that NF-kB-
mediated Smad7 induction is one of the inhibitory mechanisms
for TGF-b signaling [13]. However, one hour treatment with IL-
1b did not change the messenger RNA levels of SMAD7 in vector
control, TRAF6, or TAK1 (K63W)-expressing cells (Figure
S1C). TRAF6 is an upstream molecule of TAK1 in IL-1b and
LPS pro-inflammatory pathway, and we therefore investigated
TRAF6 as a candidate molecule mediating the IL-1b-induced
inhibitory effect. It is important to note that over-expressed
TRAF6 may form self-associated and auto-ubiquitinated
TRAF6, which is constitutively active, mimicking IL-1b or
LPS stimulation [14,15]. TRAF6 expression in HEK293 cells
suppressed TGF-b1-induced Smad3 phosphorylation as com-
pared tocontrol cells overexpressing GFP (Figure 1C). To find
out if Smad7 is required for TRAF6-mediated suppression of
Smad3 transcriptional activity, we performed SBE-luc reporter
gene assay in HepG2 cells with knock-down of Smad7. The
elevated SBE reporter activityin response to TGF-b represented
effective knock-down of Smad7. Under this condition, TRAF6
was able to suppress SBE reporter activity by showing 65% and
70% reduction in control cells (pLKO) treated with TGF-b and
Smad7 knock-down cells (shSmad7) treated with TGF-b,
respectively. (Figure S1D). This finding implies that TRAF6
may similarly suppress TGF-b/Smad3 signaling even in the cells
with reduced Smad7 expression. Near to complete knock-down
of Traf6 was achieved in 67NR mouse mammary epithelial cells
via infection with lentivirus encoding Traf6 specific shRNA. In
sh-Traf6 cells, LPS-mediated suppression of Smad3 activity
disappeared as compared to the control sh-Luc counterpart
(Figure S1E), indicating that TRAF6 might be a factor
responsible for mediating the suppressive effect of LPS on
TGF-b1-mediated Smad3 phosphoryation. HaCaT cells, due to
the sensitivity to TGF-b-induced cell growth inhibition, were
used to examine whether TRAF6 overexpressing cells give rise to
reduction of TGF-b1 target genes. The results of both
quantitative PCR and RT-PCR indicated that TRAF6 overex-
pressing cells were less sensitive to TGF-b-mediated induction of
the cell cycle inhibitors such as CDKN2B and CDKN1A and
SMAD6 (Figure 1D and Figure S1F). These results further
support the importance of TRAF6 as a critical mediator of IL-
1b-induced suppression on TGF-b signaling. The induction of
apoptosis in rat hepatoma FaO cells by TGF-b is known to be
mediated by active Smad2/3 [16]. Thus, the biological
significance was addressed by examining the suppressive role
of pro-inflammatory signaling on TGF-b-induced apoptosis in
FaO cells. The TRAF6 over-expressing FaO cells were less
sensitive to TGF-b-induced apoptosis as evidenced by decreased
cleaved-caspase3 and Smad2 phosphorylation (Figure 1E).
Induction of cleaved-caspase 3 and Smad3 phosphorylation by
TGF-b1 were decreased in LPS co-treated cells (Figure S2A). To
further investigate whether the LPS-induced inhibition of TGF-
b-induced apoptosis is dependent on NF-kB-mediated signaling,
FaO cells were infected by adenovirus containing either LacZ or
IkBaSR. IkBaSR is asuper-repressor mutant of IkBawhich
cannot be phosphorylated or degraded by NF-kB-activating
stimuli, and eventually prevents NF-kB transcriptional activation
[17]. Induction of cleaved-caspase 3 by TGF-b1w a sn o ta f f e c t e d
i nt h ep r e s e n c eo fI kBaSR, indicating that NF-kB-dependent
survival factors are less likely to play a role in this anti-apoptotic
event (Figure S2B). Moreover, apoptotic induction by TGF-b
was significantly suppressed by LPS co-treatment as demon-
strated by TUNEL and DNA fragmentation assay (Figure S2C
and S2D). These results indicated that LPS may facilitate cell
survival by suppressing Smad2/3 signaling pathways, possibly
through TRAF6.
Traf6 2/2 primary cells showed elevated sensitivity to
TGF-b1
The physiological function of Traf6 in TGF-b1-Smad2/3
signaling was further investigated in Traf6+/+ and Traf62/2
mouse embryonic fibroblasts (MEFs). Messenger RNA and protein
expression of TGF-b receptors in Traf6+/+ and Traf62/2 MEFs
appeared to be similar in both MEF cells (Figure S3A). When we
examined the sensitivity to TGF-b using the SBE-luciferase assay,
Traf62/2 MEFs showed stronger responsiveness to TGF-b than
the Traf6+/+ MEFs (Figure S3B). The sensitivity to TGF-b was
further examined by observing the dose-dependent responsiveness.
Consistent with the reporter assay, Smad2 and Smad3 phosphor-
ylation was detected at the lowest concentration of TGF-b1
(0.08 ng/ml) in Traf62/2 MEFs, and remained higher than that
of wild-type MEFs at other elevated concentrations (Figure 2A). In
addition, nuclear translocation of Smad3 occurred at an earlier
time point and with higher sensitivity to TGF-b1 in Traf6 2/2
MEFs (Figure 2B). A nuclei fractionation assay clearly showed
that, upon TGF-b1 treatment, the level of nuclear translocation of
Smad2 and Smad3 was elevated in Traf62/2 more than that of
the Traf6+/+ MEFs (Figure 2C). To demonstrate the key role of
Traf6 in LPS-induced suppression, we conducted TGF-b1/LPS
co-treatment experiments using the MEF cells. Traf62/2 MEFs
showed much stronger induction of pSmad3 by TGF-b1 treatment
than that of Traf6+/+ MEFs, which is consistent with previous
results (Figure 2D). Importantly, LPS-induced suppression of
Smad3 phosphorylation was observed only in the Traf6+/+ MEFs
as co-treated with TGF-b1/LPS, but not in the Traf62/2 MEFs,
which implies that Traf6 is playing an inhibitory role for TGF-b
signaling in non-transformed MEF cells.
TRAF6 Mediates Suppression of TGF-b Signaling
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32705TRAF6 forms a complex with TbRIII in a TGF-b1-
dependent manner
TbRIII is conventionally described as an accessory receptor that
presents the TGF-b ligand to TbRII, thereby boosting TGF-b
response [18]. However, recent studies demonstrate that TbRIII
has additional roles in regulating receptor internalization through
interaction with b-arrestin2, which is involved in terminating
TGF-b1 signaling [5]. We confirmed that TbRIII interacts withb-
arrestin2 in a TbRII- and TGF-b-dependent manner (Figure
S4A). Interestingly, a recent study showed that b-arrestin1/2
interacts with TRAF6 and suppresses TRAF6-mediated pro-
inflammatory responses [19]. Therefore, we explored the
possibility that TbRIII is involved in TRAF6-mediated suppres-
sion of TGF-b signaling, probably through the common binding
partner b-arrestin1/2. We first investigated the relationship
between TRAF6 and TbRIII in regulating TGF-b-mediated gene
induction by carrying out a CAGA12-Luc reporter gene assay
containing promoter with 12 tandem repeats of Smad3 binding
sequences. In cells expressing exogenous TbRIII, TGF-b-induced
CAGA12-Luc activation was attenuated by IL-1b co-treatment
(Figure 3A). TbRIII overexpression markedly enhanced TGF-b1
response, but TRAF6 dose-dependently inhibited TGF-b1
signaling, even in the presence of TbRIII (Figure S5A and S5B).
These results suggest that TbRIII plays a significant role in the
integration of IL-1b into TGF-b signaling. Interestingly, when the
importance of b-arrestin 1/2 was examined, the inhibitory effect of
TRAF6 on TGF-b-induced SBE-Luc reporter activity was
observed in b-arrestin1/2 2/2 MEFs (Figure S4B). This finding
suggests that b-arrestin may not play a major role in TRAF6-
mediated inhibition of TGF-b signaling. To determine how
TbRIII expression affects TRAF6-mediated inhibition of TGF-b
signaling, we generated a TbRIII knock-down HaCaT cell line by
lentiviral knock-down system. RT-PCR results verified that
TbRIII mRNA expression was almost completely blocked without
any changes in TbRI and TbRII expression (Figure S5C).
Interestingly, IL-1bfailed to suppress TGF-b1-induced Smad3
phosphorylation in the TbRIII knock-down HaCaT cells
(Figure 3B). These results indicate that IL-1b may down-regulate
TGF-b signaling through the interactions between TRAF6 and
TbRIII proteins. To explore the possibility that the suppression of
TGF-b signaling is mediated by enhancing TRAF6/TbRIII
interaction, HA-TbRIII and Myc-TRAF6 were expressed in
HEK293 cells and treated with TGF-b1 for up to 120 minutes
and followed by co-immunoprecipitation assays. Myc-TRAF6 and
HA-TbRIII were co-precipitated together only in the TGF-b-
treated cells with the most abundant association at 60 minute
stimulation (Figure 3C), suggesting that activation of TGF-
bsignaling triggers the association between TRAF6 and TbRIII.
Next, we tried to determine the importance of TRAF6 E3 ligase
activity for the formation of a complex with TbRIII. As compared
to wild-type TRAF6, the mutant TRAF6 (C85A/C87H), which
has no E3 ligase activity, was unable to interact with TbRIII
Figure 1. TRAF6 mediates IL-1b or LPS-induced suppression of TGF-b1/Smad pathway. (A) HEK293 cells were treated with TGF-b1 (0.4 ng/
ml) and/or IL-1b (2 ng/ml) as indicated. TGF-b-mediated Smad3 phosphorylation was demonstrated by anti-pSmad3 and total Smad3 antibodies. As a
loading control, a-tubulin was used. (B) SBE-Luc assay was performed in HepG2 cells. These luciferase assays were normalized by the activities of co-
transfected b-galactosidase. (C) TRAF6 or GFP was over-expressed in HEK293 cells by use of a lentiviral system. Cells were harvested after TGF-b1
addition for up to 6 hours followed by westernblotting to compare phospho-Smad2/3 levels. (D) TGF-b1 target genes, CDKN2B, CDKN1A, and SMAD6,
were detected by quantitative RT-PCR using total RNA from vector-(GFP) or TRAF6-expressing HaCaT cells treated as indicated. Human GAPDH was
used as a loading control. (E) FaO cells were infected with either control vector or Myc-TRAF6 on previous day and then treated with TGF-b alone or
together with LPS up to 8 hours. Both floating and adherent cells were harvested to compare the induction of cleaved caspase-3. TGF-b-induced
signal transduction was displayed by showing pSmad2 level. The results are representative of three independent experiments.
doi:10.1371/journal.pone.0032705.g001
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confirmed in the Duolink in situ proximity ligation assay (Olink
PLA) which enables visualization and quantification of protein
interaction when two proteins are at close proximity [20,21]. HA-
TbRIII-stable HEK293 cells were treated or untreated with TGF-
b for one hour and followed by immunodetection of endogenous
TRAF6 and HA-tagged TbRIII in the OLink PLA. The signals
from the proximally localized proteins are amplified as red dots in
the OLink PLA. The number of TRAF6/HA-TbRIII complexes
per cell was found to be significantly higher in the TGF-b1 treated
cells (visualized as red dots in Figure 3E, quantitated in Figure 3F).
To test whether TRAF6 and TbRIII association is enhanced by
activation of endogenous TRAF6, an HA-TbRIII stably express-
ing cell line was generated using the 4T07 mouse mammary tumor
cell line. The 4T07 cells were used for this experiment because
these cells express low to undetectable level of TbRIII which may
allow better endogenous TRAF6 and HA-TbRIII interaction
without major interference by endogenous TbRIII. TGF-b1
treatment induced interaction between TRAF6 and HA-TbRIII,
but co-treatment of cells with LPS and TGF-b1 further enhanced
the association of these proteins (Figure 3G). Decreased Smad2
phosphorylation in TGF-b1/LPS co-treated cells suggests that
endogenous TRAF6 is involved in LPS mediated inhibition of the
TGF-b1/Smad signaling pathway. This result clearly shows that
activated TRAF6 migrates to the plasma membrane and avidly
forms a complex with TbRIII upon TGF-b treatment.
Association of TRAF6/TbRIII is regulated by TbRII and
TbRI kinase activity
Since the TRAF6/TbRIII complex formed only after TGF-b1
stimulation, we questioned whether TbRII and/or TbRI play a
role in TRAF6/TbRIII complex formation. To test the potential
TRAF6/TbRIII interaction’s dependency on TBRII, SNU638
human gastric cancer cells, which do not express functional TbRII
[22], were used in a co-immunoprecipitation assay. TRAF6/
TbRIII complex formation was very weak in TGF-b1-treated cells
in the absence of functional TbRII (Figure 4A); however, TRAF6
binding to TbRIII was readily detected upon exogenous
expression of TbRII and TGF-b1 treatment. Next, we investigated
if TbRI is involved in the TRAF6/TbRIII complex formation in
Tgfbr12/2 MEFs. Whereas trivial interaction of TRAF6/TbRIII
was detected in the absence of exogenous TbRI expression, the
perceptible association of TRAF6/TbRIII was induced 60 min
post treatment of TGF-b1 only in Tgfbr12/2 MEFs expressing
exogenous TbRI (Figure 4B). This finding implies that TbRI as
well as TbRII activation by TGF-b is critical mechanism for the
induction of TRAF6/TbRIII complex formation. Therefore, these
results indicate that intact TbRII and TbRI expression are
Figure 2. Traf6-deficient primary cells show a higher sensitivity to TGF-b1. (A) Wild-type and Traf6 2/2 MEFs were grown in 6-well plates
and harvested for immunoblotting. TGF-b1 sensitivity in Traf6+/+ and Traf62/2 MEF cells were depicted by comparing pSmad2/3 post treatment of
various dose of TGF-b1. (B) Cells were treated with TGF-b1 (0.4 ng/ml) for the indicated time and immunostaining was carried out as described in
materials and methods using an anti-Smad3 antibody. DAPI staining illustrated the compartment of nuclei. (C) The nuclei fractions were isolated from
MEFs treated with TGF-b1 in a time course up to 2 hours. Lamin A/C from the nuclear fraction indicated equal loading. Density of detected Smad2
and Smad3 was normalized by lamin A/C and is shown as fold increase. (D) Wild-type and Traf6-deficient MEFs were treated with TGF-b1 and/or LPS
as indicated and then the level of p-Smad3 and IkBa were compared. IkBadegradations by LPS were observed only in the Traf6+/+ MEF, but not in
the Traf62/2 MEF. The results are representative of three independent experiments.
doi:10.1371/journal.pone.0032705.g002
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b stimulation. To further elucidate the detailed mechanism, we
examined whether TbRI kinase activity is required for TRAF6/
TbRIII interaction; this was examined by the use of wild-type
TbRI, a kinase inactive form of TbRI (K232R; KR), and a
constitutively active form of TbRI (T204D; TD), in co-
immunoprecipitation assay. As anticipated, the constitutively
active form of TbRI (TD) significantly enhanced the interaction
between TRAF6 and TbRIII, whereas TbRI wild-type and TbRI
(KR) showed respectively moderate and negligible levels of
interaction (Figure 4C), suggesting that TbRI kinase activity is
important for promoting the TRAF6/TbRIII association. This is
further confirmed by demonstrating that the association of
TRAF6/TbRIII was largely reduced in cells pre-treated with
IN-1130, a TbRI-specific kinase inhibitor [23] (Figure 4D).
Additionally, the importance of the TbRI kinase activity was
visualized and quantified using the Olink PLA. In the experiment,
exogenous TRAF6 and HA-TbRIII were expressed in HEK293
cells and treated with TGF-b1 in the presence or absence of IN-
1130. Then, cells were immunostained with anti-Myc (9E10) and
anti-HA (Y11) to detect proximally located antigens. As a result,
Myc-TRAF6 and HA-TbRIII co-localized in the TGF-b-treated
cells, whereas IN-1130-treated cells showed negligible levels of
signal, similar to untreated controls (Figs. 4E and 4F). This result
validates the importance of TbRI kinase activity in TRAF6 and
TbRIII complex formation. Interestingly, there has been an
observation that TRAF6 binds to TbRI via the TRAF6 consensus
binding motif [24]. We therefore attempted to test whether the
consensus binding motif for TRAF6 found on TbRI would affect
the interaction between TRAF6 and TbRIII. We performed a co-
immunoprecipitation assay with cells expressing TRAF6, TbRIII,
and either TbRI (KR), TbRI (TD), or TbRI (TD-E161A), a TbRI
with mutation of the TRAF6 consensus binding motif. TRAF6/
TbRIII interaction was mostly abrogated by the kinase-inactive
TbRI mutant (KR), but only slightly decreased by the TRAF6
consensus binding motif mutant (E161A) of TbRI (TD)
(Figure 4G). These results suggest that the TRAF6-TbRIII
interaction occurs independently of the TRAF6-TbRI interaction.
TbRIII is a substrate of TbRI kinase
The cytoplasmic domain of TbRIII has been demonstrated for
TbRII interaction and become phosphorylated when TbRII is
over-expressed, leading to the dissociation of TbRIII from the
TbRII/TbRI complex [25]. Therefore, we speculated that TbRI
may be the Ser/Thr kinase that phosphorylates TbRIII upon
TGF-b1 stimulation. HEK293 cells stably expressing TbRIII were
Figure 3. TRAF6 forms a complex with TbRIII in response to TGF-b1. (A) CAGA12-Luciferase assays were performed in HepG2 cells. The
plasmids encoding HA-TbRIII, TRAF6, CAGA12-Luc, and Renilla-luc reporter gene were transfected as indicated and, on the next day, TGF-b1 (0.4 ng/
ml) and/or IL-1b (20 ng/ml) was added for 16 hours. The obtained relative luciferase units(RLU) were normalized by renilla luciferase activities. (B)
Using the control and TbRIII knock-down HaCaT cells, TGF-b1 (0.4 ng/ml) and/or IL-1b (20 ng/ml) were treated as shown for up to 3 hours. The level
of total Smad3 and phospho-Smad3 protein was detected by immunoblotting. For the control of equal loading, b-actin was used. (C) HEK293 cells
stably expressing HA-TbRIII were transfected with Myc-Traf6 plasmids and then treated with TGF-b1. Cells were harvested at various times and were
subjected to immunoprecipitation with anti-HA antibody. Co-immunoprecipitated TRAF6 was detected with anti Myc antibody. (D) Complex
formation ability between TbRIII and TRAF6 wild-type or the TRAF6 (C85A/H87A) E3 ligase mutant was compared after TGF-b stimulation for an hour.
(E) According to the manufacturer’s protocol, interaction was visualized by in situ proximity ligation assay (O-link) with proximity probes directed
against TRAF6 and TbRIII using Alexa 555 labeling (red). Endogenous TRAF6 was co-localized with HA-TbRIII along the plasma membrane in the
presence of TGF-b (red blobs). Bar=2.5 mm. (F) Quantification of blobs per cell was carried out by semi-automated image analysis using the freeware
software BlobFinder V 3.0. (G) HA-TbRIII-stably expressing 4T07 mouse mammary cancer cells were treated with TGF-b and LPS for one hour. Co-
immunoprecipitation was carried out using anti-HA antibody to query interaction with endogenous TRAF6. The results are representative of three
independent experiments.
doi:10.1371/journal.pone.0032705.g003
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immunoprecipitated for HA-TbRIII. Phospho-TbRIII was assess-
ed using a phospho-Serine-specific antibody (Figure 5A). The
phospho-form of TbRIII was detected at maximum intensity at
60 minutes after TGF-b1 stimulation, which agreed with the
results of TbRIII-TRAF6 interaction shown in Figure 3C. This
prompted us to verify whether TbRI directly phosphorylates the
cytoplasmic domain of TbRIII. We utilized GST protein-tagged
deletion mutants for TbRIII cytoplasmic domain, as illustrated in
Figure 5B. HA-TbRI (TD) was expressed in HEK293T cells and
then immunoprecipitated with anti-HA antibody for an in vitro
kinase assay. Consistent with our hypothesis, TbRI (TD) strongly
phosphorylated the GST-tagged cytoplasmic domain of TbRIII
and the TbRIII-835 mutant, but not the TbRIII-823 mutant
(Figure 5C), implying that TbRIII possesses a potential phosphor-
ylation site(s) for TbRI kinase between amino acids 823 and 835.
The specific activity of the TbRI (TD) kinase in this assay was
determined by addition of 1 mM IN-1130, which almost
completely blocked not only auto-phosphorylation of TbRI (TD)
but also ablated GST-TbRIII phosphorylation (Figure 5C). Next,
to identify the exact phosphorylation site, we prepared GST-
TbRIII-C proteins with point mutations at the four serine residues
between amino acids 823–835 into alanine, respectively
(Figure 5B), and then performed a TbRI (TD) kinase assay. As
shown in Figure 5D, TbRI (TD) was able to phosphorylate GST-
TbRIII-C and mutants S826A, S830A, and S834A, but was
unable to phosphorylate mutant S829A, indicating that residue
Ser 829 is a potential phosphorylation target of TbRI (TD). To
determine whether phosphorylation of TbRIII may enhance the
association of TbRIII with TRAF6, we performed a GST pull-
down assay with TbRIII-C-GST fusion proteins that were
unphosphorylated or phosphorylated by TbRI (TD) in vitro.
TRAF6 strongly interacted with TbRIII-C activated by TbRI
(TD) (Figure 5E). This result clearly showed that the TbRI-
mediated TbRIII phosphorylation is a key mechanism of the
TRAF6/TbRIII complex formation. To determine the minimal
binding domain of TbRIII, we designed a GST pull-down assay
with GST-TbRIII-C deletion mutants. While TRAF6 was able to
bind TbRIII-C and the TbRIII-835 mutant phosphorylated by
TbRI (TD), it could not bind the TbRIII-823 mutant in which the
TbRI (TD)-induced phosphorylation site was deleted (Figure 5F).
These results indicate that the TbRIII region between amino acids
823–835, phosphorylated by TbRI (TD), encompasses a site
responsible for interaction with TRAF6. We therefore set up an
Olink assay to demonstrate the requirement of TbRIII S829
phosphorylation for interaction with TRAF6. In the Olink
Figure 4. Association of TRAF6/TbRIII is regulated by functional TbRII and TbRI. (A) Myc-TRAF6, HA-TbRIII, and/or Flag-TbRII were expressed
in SNU638 human gastric cancer cells and treated with TGF-b1 for 60 min. Immunoprecipitation and immunoblotting were carried out to elucidate
the requirement of TbRII for TRAF6/TbRIII interaction. (B) TRAF6 and TbRIII interaction in TbRI2/2 MEFs in the presence or absence of exogenous
TbRI expression. (C) TRAF6/TbRIII interaction in the presence of wild-type, kinase inactive (KR: K232R), and constitutively active (TD: T204D) TbRI in
HEK293 cells. (D) Interaction between TRAF6 and TbRIII in the presence of IN-1130 (0.1 mM), a specific inhibitor of TbRI kinase. (E) Olink assay for
TRAF6 and TbRIII interaction in the presence of TGF-b and/or IN-1130. Transfected cells were counterstained with Alexa 488-labeled HA antibody to
HA-TbRIII (green), and the nuclei were stained with Hoechst 33342 (blue). Bar=2.5 mm. (F) The number of in situ PLA signals (red blobs) per cell was
counted by semi-automated image analysis. (G) Co-immunoprecipitation analysis was conducted to elucidate the function of TbRI in TRAF6/TbRIII
interaction. TbRI mutants KR, TD, and TD (E161A) mutated in TRAF6 consensus binding motif in TbRI (TD) were used. The results are representative of
three independent experiments.
doi:10.1371/journal.pone.0032705.g004
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TbRIII (S829A) was weak and unchanged in response to TGF-b
(Figs. 5G and 5H). These results indicate that TbRIII is a novel
substrate of TbRI kinase, and that the phosphorylation of TbRIII
at S829 by acitivated TbRI kinase is playing a major role for
TRAF6/TbRIII interaction.
TRAF6 dissociates TbRIII from TbRII/TbRI complex
In order to elucidate the underlying mechanism by which
TRAF6 suppresses TGF-b/Smad signaling through the associa-
tion with TbRIII, we hypothesized that TRAF6 may disrupt
TbRIII/TbRII complex formation, which is critical in boosting
cellular TGF-b1 responses [18]. We found that exogenous
expression of TRAF6 interrupted TGF-b1-induced TbRIII and
TbRII interaction (Figure 6A). Furthermore, the level of TbRII
bound to TbRIII was inversely related to the level of TRAF6
expression (Figure 6B). The physiological significance of the
influence of TRAF6 on TGF-b signaling was determined by
examining endogenous TRAF6 bound to TbRIII in cells treated
with TGF-b1 alone or with IL-1b. In the TGF-b1-treated cells,
TbRIII/TbRII association persisted up to 60 minutes (Figure 6C).
However, in the cells treated with both TGF-b1 and IL-1b, the
level of TbRIII-bound TbRII decreased close to the basal level,
while the level of TbRIII-associated TRAF6 increased at
60 minutes. We observed the interaction between TbRIII and
endogenous TRAF6 in cells treated with only TGF-b (Figure 3G
Figure 5. TbRI-mediated phosphorylation of TbRIII at Ser 829 induces preferential binding to TRAF6. (A) HEK293 cells stably expressing
TbRIII were treated with TGF-b1 over a time course. HA-tagged TbRIII was purified by immunoprecipitation and evaluated the change in serine
phosphorylation. (B) The transmembrane (TM) and cytoplasmic domains of TbRIII were fused with GST protein. Amino acid sequences for cytoplasmic
full-length (TbRIII-C) and deletion mutants (TbRIII-835, TbRIII-823) of GST-TbRIII fusion proteins are illustrated. The potential phosphorylation sites are
underlined, and were substituted from Ser to Ala for subsequent experiments. (C) Equal amounts of GST-TbRIII-C and deletion mutants were
subjected to in vitro kinase assay using constitutively active TbRI (TD). IN-1130 (1 mM), a specific inhibitor of TbRI, was added to demonstrate the
specificity of kinase reactions. (D) The potential phosphorylation sites on GST-TbRIII were mutated to Ala and determined the TbRI (TD)-mediated
phosphorylation site of TbRIII. (E) A GST pull-down assay was performed using GST-tagged TbRIII-C deletion mutant against cell lysates expressing
Myc-TRAF6 proteins. The phosphorylation by TbRI (TD) significantly increased TbRIII and TRAF6 interaction in vitro.( F) GST-tagged TbRIII-C deletion
mutants, subjected to an in vitro TbRI (TD) kinase assay, were used to define the region of TbRIII that interacts with TRAF6. (G) O-link assay was
conducted for visualization of interaction between TRAF6 and TbRIIIS829A in HEK 293T cells. Bar=2.5 mm. (H) The number of in situ PLA signals per
cell was counted by semi-automated image analysis. The results are representative of three independent experiments.
doi:10.1371/journal.pone.0032705.g005
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TbRII complex (Figure 6C). The dissociation is likely to occur
only in the case of abundant association of TRAF6 to TbRIII
upon LPS or IL-1b co-stimulation (Figure 6C). Taken together,
our study suggests a model in which simultaneous treatment with
IL-1b/LPS and TGF-b1 provokes robust interaction between
TRAF6 and TbR complex while TGF-b alone induces mild
interaction of these molecules. Subsequently, IL-1b or LPS
suppresses TGF-b/Smad signaling by increasing an interaction
between TRAF6 and TbRIII, which is dependent on active TbRI-
mediated phosphorylation of TbRIII at Ser829 (Figure 6D). This
interaction between TRAF6 and TbRIII is possibly resulted from
dissociation of TbRIII from the TbRII/TbRI complex, thereby
contributing to the down-regulation of Smad2/3-dependent
cellular responses.
Here we have demonstrated that TRAF6, activated by IL-1b or
LPS, suppresses TGF-b1/Smad pathways through interaction
with TbRIII upon TGF-b1 stimulation. In general, inflammation
is tightly regulated and resolved by the induction of anti-
inflammatory cytokines [8]. Once this regulatory balance is
disturbed, non-specific stimulation and activation of inflammatory
cells may lead to increased production and release of potently
destructive immunological and inflammatory molecules. TGF-b1
is a pleiotropic cytokine with considerable anti-inflammatory
properties. Deficiency of TGF-b1 signaling in the intestine
contributes to the development of inflammatory bowel disease,
Figure 6. TRAF6 enhances dissociation of TbRIII from TbRII/TbRI complex. (A) The interaction between TbRIII and TbRII was enhanced by
TGF-b1, and interfered by TRAF6 expression in HEK293 cells. (B) Over-expression of TRAF6 in HEK293 HA-TbRIII-stable cells interfere the interaction of
Flag-TbRII and HA-TbRIII in a dose-dependent manner. (C) HEK293 HA-TbRIII-stable cells were treated as indicated, and were subjected to
immunoprecipitation. HA-TbRIII interacted with endogenous TbRII upon TGF-b1 treatment. The level of endogenous TbRII bound to HA-TbRIII was
markedly decreased in TGF-b1/IL-1b co-treated cell, while the level of endogenous TRAF6 bound to HA-TbRIII was increased s. These results are
representative of three independent experiments. (D) A proposed model of IL-1b/LPS-induced suppression of the TGF-b pathway.
doi:10.1371/journal.pone.0032705.g006
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regulating immune homeostasis in the intestine [26,27]. It is well
known that inflammatory bowel diseases predispose cancer
formation in the intestinal tract. The increased and persistent
pro-inflammatory cytokines in the tumor microenvironment play a
major role for inducing malignancy [6,7,8]. For instance,
improper regulation of IL-1b signaling has been shown to
potentiate neoplastic risk and ultimately induce tumor progression
[8]. In fact, polymorphisms of IL1B promoter which enhance IL-
1b expression are associated with increased risk of developing
human gastric cancer [28,29]. The study performed in IL-1b
knock-out mice suggested that IL-1b enabled local tumor growth
and/or metastasis to the lung [30]. In addition, decreased TbRIII
expression was closely correlated with tumor progression in
various human cancers including breast, lung, prostate, pancre-
atic, ovarian, and renal cancers [31], supporting the idea that
TbRIII-mediated regulation of normal epithelial cells may
contribute to prevent tumor progression.
A recent report also showed that Traf6 inhibits Th17 T cell
differentiation through the downregulation of Smad signaling [32].
Although the detailed mechanism of this inhibition has not been
elucidated in T cells, it supports that Traf6 is partly responsible for
inhibiting the TGF-b-induced Smad2/3 signaling pathway in vivo.
Thus, constitutive activation of TRAF6 by abundant IL-1b in the
lesion may contribute to the early stages of tumor development, at
least in part, via inhibition of Smad2/3 tumor suppressor pathway.
It is suggested that TRAF6 interacts with TbRI/TbRII complex
upon stimulation of TGF-b and mediates activation of p38/JNK
MAPKs via TRAF6/TAK1 axies without inhibition of Smad2/3
signaling [24,33]. We observed that TRAF6 involved in the
dissociation of TbRIII from TbRII/I complex in a dose-dependent
fashion (Figure 6) and interaction of TRAF6/TbRIII was increased in
LPS/TGF-bco-treated cells (Figure 3G). These results suggest a model
in which TRAF6 may differently regulate TGF-b-induced Smad2/3
and/or p38/JNK activation depending on the amount of TRAF6
interacting with TGF-breceptor complex. These regulatory mecha-
nisms are potentially important to determine TGF-b responses such as
cell growth arrest, apoptosis, or epithelial-mesenchymal transition.
In summary, our data delineated a key molecular mechanism
that IL-b or LPS inhibits anti-inflammatory TGF-b/Smad
signaling through TRAF6 and TbRIII association in TGF-b-
and TbRI kinase-regulated manner. Although the antagonistic
effects of IL-1b/LPS on TGF-b1 signaling may occur at multiple
molecular levels, a fine modulation of the TGF-b receptors may
critically affect cell fates by changing the kinetics of Smad2/3
phosphorylation. By this mechanism, IL-1b may potentiate
inflammatory responses, and chronic inflammation may further
contribute to tumor progression by suppressing the TGF-b anti-
inflammatory and tumor suppressor pathways.
Materials and Methods
Cell culture and reagents
HepG2, HEK293, HEK293T, 67NR, 4TO7, and 4T1 cells
were obtained from ATCC and HaCaT cells were kindly provided
by Dr. Stuart Yuspa (National Cancer Institute, Bethesda, MD).
TRAF6-deficient mouse embryonic fibroblasts and b-arrestin-
deficient MEFs were gifted from J. Inoue (Keio University) and R.
Lefkowitz (Duke University), respectively. FaO cell were also
kindly gifted by Dr. I. Lim (Aju university). HaCaT, HepG2, FaO,
HEK293, and HEK293T cells were grown in DMEM, and 67NR
and 4T07 breast cancer cell lines were grown in RPMI
supplemented with 10% (vol/vol) FBS, penicillin (100 units/ml),
and streptomycin (100 mg/ml; Invitrogen, Rockville, MD). Cells
with stable expression of TbRIII were generated by transfection
with pCDNA3.1-HA-TbRIII and then selected as a pool in
selection medium containing neomycin. Antibodies specific for
hemagglutinin (Y-11 or F-7), Myc (9E10), TRAF6 (H-274), TbRII
(C-16), and TbRI (V-22) were purchased from Santa Cruz;
antibodies to Flag (anti-Flag; M2) and anti-b-actin (AC-15) were
from Sigma; specific antibodies for p-Smad2, p-Smad3, and total
Smad2 were from Cell Signaling; anti-Smad3 and anti-phospho-
serine specific antibodies were from Zymed Laboratories.
TUNEL assay
TGF-b-induced cell death in FaO cells was demonstrated using
In Situ Cell Death Detection Kit Fluorescein (Roche) according to
manufacturer’s protocols, which can detect single- and double-
stranded DNA breaks that arise at early stages of apoptosis.
DNA Fragmentation assay
Following treatment of FaO cells with TGF-b and/or LPS for
overnight, all of the adherent and floating cells were collected and
subjected to genomic DNA preparation. The collected cells were
resuspended in 400 ml extraction buffer (0.5% SDS, 0.1 M NaCl,
0.01 M EDTA, 0.02 M Tris-HCl (pH 7.6), and proteinase K
(100 mg/ml)) and followed by incubation at 60uC for 2 hours. The
lysates were resuspended with 200 ml of 6 M NaCl, mixed
thoroughly, and placed on ice for 5 minutes. After spin down
the lysates for 10 minutes at 13,000 rpm, the 400 ml supernatants
were transferred and mixed with 100% ethanol to precipitate
genomic DNA. The precipitated DNA was harvested and
dissolved in TE buffer. Finally, the DNA was incubated for 1–
2 hours at 56uC, and measured DNA concentration and loaded in
1% agarose gel with equal amount of genomic DNA.
Immunofluorescence microscopy
Wild-type and Traf6-deficient MEF cells were grown on 22-mm
glass coverslips in a CO2-humidified incubator for 24 h. Smad3
was detected by incubation at 4uC with anti-Smad3 rabbit
polyclonal (Zymed Laboratories Inc.). The images were acquired
with Nikon microscope by using MetaMorph software.
Nuclear fractionation and quantification
Nuclear and cytoplasmic fractionations were performed accord-
ing to previously described methods [34]. Density of detected
Smad2 and Smad3 was quantitated using ImageJ software and
marked as a fold change.
Knock-down and over-expression using Lentiviral
infection system
Knockdown of endogenous Traf6 and TbRIII gene expression
was carried out using the lentivirus shRNA expression system and
experimental method as previously described [10]. The target
sequence of mouse traf6 nucleotide 618–637 (AGCTGTCCTCT-
GGCAAATATC), human TGFBR3 nucleotide 1878–1897 (ATG-
GTGTGGTCTACTATAA), or control Luciferase nucleotide was
used. For over-expression, the TRAF6 gene was introduced into
pCAG-MCS-W Lentiviral vector and transfected for viral packaging.
In vitro site-directed mutagenesis
In order to generate mutant constructs (S826A, S829A, S830A,
and S834A) for C-term of TbRIII (TbRIII-C), we performed in
vitro site-directed mutagenesis reaction by employing Quick-
Change Site-directed mutagenesis kit (Stratagene). We designed
specific primers for each mutant construct (supplementary data)
according to the manufacturer’s protocol.
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The TbRI kinase assay was performed as described [23] and
GST-TbRIII deletion mutant proteins were prepared according to
the manufacturer’s protocol (Amersham Bioscience). The trunca-
tion mutants of TbRIII-835 and TbRIII-823 were generated by
introducing termination codon, according to the instruction of site-
directed mutagenesis kit (Stratagene). The phospho-labeled
proteins were detected by autoradiography.
Proximity ligation assay (PLA)
PLAwasperformedtovisualizeprotein–proteininteractionsusing
the reagent kit from Olink Bioscience. In brief, oligonucleotide
conjugated ‘probe’ antibodies are directed against primary antibod-
ies. Annealing of the ‘probes’ occurs when the target proteins are in
close proximity, which initiates the amplification of a Texas red
reporter signal [21]. After TbRIII-myc and TRAF6-myc transfec-
tion, HEK 293T cells were treated with TGF-b1f o r1h r,0 . 1mM
IN-1130 for 2 hr. Cells were washed with chilled PBS and fixed with
acetone for 20 mins, and incubated overnight with mouse anti-myc
(1:100, Santa Cruz, sc-40) and rabbit anti-HA (1:100, Santa Cruz,
sc-805) at 4uC. Proximity ligation was performed according to the
manufacturer’s protocol using the Duolink Detection Kit with PLA
PLUS and MINUS Probes for mouse and rabbit (Olink Bioscience).
Hoechst stain was included in the Duolink Detection Kit while anti-
rabbit Alexa 488 (1:500; Invitrogen Inc.) was added during the
detection reaction. Specimens were mounted with Vecta-shield
mounting media (Vector Laboratories) and examined with and
confocal microscope (Carl Zeiss, LSM 710). The number of in situ
PLA signals per cell was counted by semi-automated image analysis
using the freeware software BlobFinder V 3.0.
Supporting Information
Figure S1 TRAF6 mediates IL-1b/LPS signaling for
suppression of TGF-b/Smad signaling. (A) HaCaT cells
were treated with TGF-b, IL-1b, and/or LPS as indicated. Altered
pSmad2/3levelsdemonstratedthemitigatedTGF-bresponsesupon
IL-1b or LPS co-treatment. (B)I L - 1 b-induced NF-kB promoter
activation is blocked by TAK1 (K63W) expression. (C)S m a d 7
messenger RNA expression is not affected by exogenous expression
of TRAF6 or TAK1 (K63W) or addition of IL-1b for 1 hour in
HepG2 cells. (D) TRAF6-mediated suppression of SBE-promoter
activity following TGF-b addition was examined in HepG2 cells
which are knocked down smad7 expression by lenti-shSmad7 or
pLKO control. (E) 67NR cells were infected with lentivirus
containing either control sh-Luciferase (sh-Luc) or sh-TRAF6 and
then selected by Puromycin (2 mg/ml) for a week. TRAF6 protein
expression was ablated in sh-TRAF6 infected cells, while b-actin
expression wasunaffected.Cells were examined to compare the level
of phospho-Smad2/3 in response to TGF-b1 (0.4 ng/ml) with or
without LPS (50 ng/ml). (F) Myc-TRAF6 or GFP over-expressing
HaCaT cells were treated with TGF-b for up to 6 hours and then
harvested for RT-PCR. TGF-b target genes (CDKN1A and SMAD6)
were compared in control and exogenous TRAF6-expressing cells.
(TIF)
Figure S2 LPS antagonized TGF-b-induced apoptosis of
FaO cells in a NF-kB independent manner. (A) FaO cells
were treated with TGF-b or TGF-b/LPS for the time as indicated
(TGF-b1(5 ng/ml), LPS (50 ng/ml)). The change of pSmad3 level
was shown upon TGF-b alone or simultaneous addition of TGF-
b/LPS. (B) FaO cells were infected with either adenoviral LacZ or
IkBasr and treated with TGF-b alone or together with LPS up to
8 hours. Cells were harvested to compare the induction of cleaved
caspase-3. (C) FaO cells were treated with TGF-b and/or LPS as
indicated for overnight followed by TUNEL assay. The morpho-
logic difference was shown in photographs with phase contrast
(PC) and fluorescent microscopy (TUNEL) at 406. (D) FaO cells
were stimulated with TGF-b and/or LPS. The adherent and
floating cells were collected and subjected to DNA fragmentation
assay. Equal amount of genomic DNA was loaded.
(TIF)
Figure S3 The inhibitory role of Traf6 in wild-type and
Traf6 2/2 MEFs for TGF-b/Smad signaling Wild-type
and Traf6 2/2 MEFs were grown in 6-well plates and harvested
for total RNA or lysed for immunoblotting. (A, left) RT-PCR was
performed to show expression of endogenous Tgfbr1, 2, 3, and Traf6
messenger RNA. (A, right) Immunoblotting was carried out for
TbRI, TbRII, and Traf6 proteins. b-actin was used as a loading
control. (B) SBE-Luc reporter gene assay was performed in wild-
type and Traf6 2/2 MEFs with or without TGF-b1 treatment
(0.4 ng/ml). The SBE promoter-derived luciferase activity was
normalized by co-transfected b-galactosidase and plotted as a fold
induction by setting 1wtih unstimulated control cells.
(TIF)
Figure S4 b-arrestin2 interacts with TbRIII in a TGF-b
and TbRII dependent manner, but does not play a key
role for Traf6-mediated inhibition of TGF-b signaling.
(A) A schematic diagram for Myc-tagged b-arrestin2 deletion
mutants that were used in subsequent co-immunoprecipitation
assays (upper). The full-length and N-terminal portion of b-
arrestin2 show a capacity for TbRIII binding in a manner that is
TbRII- (left) and TGF-b1- (right) dependent. (B) SBE-Luciferase
assay shows that TRAF6 inhibits TGF-b signaling in b-arrestin2
+/+, b-arrestin2 2/2, and b-arrestin1/2 2/2 MEFs.
(TIF)
Figure S5 Suppression of TbRIII-mediated SBE pro-
moter activation by TRAF6 and knock-down of TbRIII in
HaCaT cells (A) SBE-Luciferase assays were performed in
HepG2 cells. The plasmids encoding HA-TbRIII, TRAF6, SBE-
Luc, and b-galactosidase gene were transfected as indicated and,
on the next day, followed by TGF-b1 (0.4 ng/ml) addition for
16 hours. The obtained relative luciferase units (RLU) were
normalized by b-galactosidase activities. (B) TRAF6 mediated
suppression of TGF-b signaling was further examined in the
presence of TbRIII with increasing amount of TRAF6 expression.
(C) HaCaT cells were infected with lentivirus encoding sh-TbRIII
or control sh-Luciferase. RT-PCR was carried out to demonstrate
the knock-down of TbRIII mRNA. TGFBR1 and TGFBR2 mRNA
expression was unaffected by sh-TbRIII expression. GAPDH
indicated that equal amount of RNA was used in RT-PCR.
(TIF)
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